AC
CRNX icon

Athanor Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Athanor Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,459
Closed -$195K – 718
2020
Q3 		$195K Sell
12,459
-3,905
-24% -$59.7K 0.01% 493
2020
Q2 		$287K Buy
+16,364
New +$279K 0.01% 422

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Athanor Capital's CRNX Position: Q4 2020 in Review

Athanor Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2020, closing a stake of 12,459 shares — an estimated $195K sold.

Athanor Capital first reported a position in CRNX in Q2 2020 and held it in 2 quarters. The position peaked at $287K in Q2 2020. 85 funds tracked by Wall St. Rank hold CRNX as of Q4 2020.

  • Athanor Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Athanor Capital sold 12,459 Crinetics Pharmaceuticals shares in Q4 2020, an estimated $195K.
  • Athanor Capital first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Athanor Capital's Crinetics Pharmaceuticals position peaked at $287K in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2020.

Based on Athanor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.